These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 20411785)

  • 1. Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes.
    García-Arencibia M; García C; Kurz A; Rodríguez-Navarro JA; Gispert-Sáchez S; Mena MA; Auburger G; de Yébenes JG; Fernández-Ruiz J
    J Neural Transm Suppl; 2009; (73):269-75. PubMed ID: 20411785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice.
    González S; Mena MA; Lastres-Becker I; Serrano A; de Yébenes JG; Ramos JA; Fernández-Ruiz J
    Brain Res; 2005 Jun; 1046(1-2):195-206. PubMed ID: 15882845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease.
    Lastres-Becker I; Berrendero F; Lucas JJ; Martín-Aparicio E; Yamamoto A; Ramos JA; Fernández-Ruiz JJ
    Brain Res; 2002 Mar; 929(2):236-42. PubMed ID: 11864629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.
    Lastres-Becker I; Cebeira M; de Ceballos ML; Zeng BY; Jenner P; Ramos JA; Fernández-Ruiz JJ
    Eur J Neurosci; 2001 Dec; 14(11):1827-32. PubMed ID: 11860478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
    González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
    Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain.
    Hurley MJ; Mash DC; Jenner P
    J Neural Transm (Vienna); 2003 Nov; 110(11):1279-88. PubMed ID: 14628192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cannabinoid-1 receptor is abundantly expressed in striatal striosomes and striosome-dendron bouquets of the substantia nigra.
    Davis MI; Crittenden JR; Feng AY; Kupferschmidt DA; Naydenov A; Stella N; Graybiel AM; Lovinger DM
    PLoS One; 2018; 13(2):e0191436. PubMed ID: 29466446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia.
    Julian MD; Martin AB; Cuellar B; Rodriguez De Fonseca F; Navarro M; Moratalla R; Garcia-Segura LM
    Neuroscience; 2003; 119(1):309-18. PubMed ID: 12763090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen.
    Romero J; Berrendero F; Pérez-Rosado A; Manzanares J; Rojo A; Fernández-Ruiz JJ; de Yebenes JG; Ramos JA
    Life Sci; 2000; 66(6):485-94. PubMed ID: 10794065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice.
    Cabranes A; Pryce G; Baker D; Fernández-Ruiz J
    Brain Res; 2006 Aug; 1107(1):199-205. PubMed ID: 16822488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions.
    Romero J; Garcia-Palomero E; Castro JG; Garcia-Gil L; Ramos JA; Fernandez-Ruiz JJ
    Brain Res Mol Brain Res; 1997 Jun; 46(1-2):100-8. PubMed ID: 9191083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
    Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
    Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.
    Ooms M; Rietjens R; Rangarajan JR; Vunckx K; Valdeolivas S; Maes F; Himmelreich U; Fernandez-Ruiz J; Bormans G; Van Laere K; Casteels C
    Neurobiol Aging; 2014 Dec; 35(12):2858-2869. PubMed ID: 25018107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice.
    Steiner H; Bonner TI; Zimmer AM; Kitai ST; Zimmer A
    Proc Natl Acad Sci U S A; 1999 May; 96(10):5786-90. PubMed ID: 10318962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A spontaneous deletion of α-synuclein is associated with an increase in CB1 mRNA transcript and receptor expression in the hippocampus and amygdala: effects on alcohol consumption.
    López-Jiménez A; Walter NA; Giné E; Santos Á; Echeverry-Alzate V; Bühler KM; Olmos P; Giezendanner S; Moratalla R; Montoliu L; Buck KJ; López-Moreno JA
    Synapse; 2013 Jun; 67(6):280-9. PubMed ID: 23345080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kappa- and delta-opioid receptor functional activities are increased in the caudate putamen of cannabinoid CB1 receptor knockout mice.
    Urigüen L; Berrendero F; Ledent C; Maldonado R; Manzanares J
    Eur J Neurosci; 2005 Oct; 22(8):2106-10. PubMed ID: 16262648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia.
    Rojo-Bustamante E; Abellanas MA; Clavero P; Thiolat ML; Li Q; Luquin MR; Bezard E; Aymerich MS
    Neurobiol Dis; 2018 Oct; 118():64-75. PubMed ID: 29936234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subchronic haloperidol increases CB(1) receptor binding and G protein coupling in discrete regions of the basal ganglia.
    Andersson M; Terasmaa A; Fuxe K; Strömberg I
    J Neurosci Res; 2005 Oct; 82(2):264-72. PubMed ID: 16175569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease.
    Solano SM; Miller DW; Augood SJ; Young AB; Penney JB
    Ann Neurol; 2000 Feb; 47(2):201-10. PubMed ID: 10665491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.